$Johnson & Johnson (JNJ.US)$ $SINOPHARM (01099.HK)$ COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna (MRNA.US)$ , $ASTRAZENECA PLC (AZNCF.US)$ and $Pfizer (PFE.US)$ and partner $BioNTech (BNTX.US)$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline (GSK.US)$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

$Pfizer (PFE.US)$ first time trailing this stock was priced around USD 42 ish and monitored for a month but the movement looked side ways... I was telling myself come back to it again at a later time , just a few months now it hike to USD52…since when this stock was showing such volatility? I missed this round of the boat.